- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01785875
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
April 1, 2019 updated by: Amgen
A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
This study is designed to describe the long-term safety and efficacy of etelcalcetide (AMG 416) for the treatment of SHPT in adults with CKD on hemodialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
891
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Research Site
-
St Leonards, New South Wales, Australia, 2065
- Research Site
-
Westmead, New South Wales, Australia, 2145
- Research Site
-
-
Queensland
-
Brisbane, Queensland, Australia, 4102
- Research Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Research Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Research Site
-
Parkville, Victoria, Australia, 3050
- Research Site
-
-
-
-
-
Graz, Austria, 8036
- Research Site
-
Linz, Austria, 4010
- Research Site
-
Wien, Austria, 1090
- Research Site
-
-
-
-
-
Aalst, Belgium, 9300
- Research Site
-
Baudour, Belgium, 7331
- Research Site
-
Bonheiden, Belgium, 2820
- Research Site
-
Brussel, Belgium, 1090
- Research Site
-
Brussels, Belgium, 1200
- Research Site
-
Bruxelles, Belgium, 1020
- Research Site
-
Leuven, Belgium, 3000
- Research Site
-
Liege, Belgium, 4000
- Research Site
-
Liège, Belgium, 4000
- Research Site
-
Roeselare, Belgium, 8800
- Research Site
-
Tournai, Belgium, 7500
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Research Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6R 3J7
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Research Site
-
Montreal, Quebec, Canada, H4J 1C5
- Research Site
-
Montreal, Quebec, Canada, H1T 2M4
- Research Site
-
-
-
-
-
Hradec Kralove, Czechia, 500 05
- Research Site
-
Novy Jicin, Czechia, 741 01
- Research Site
-
Plzen, Czechia, 301 00
- Research Site
-
Praha 4, Czechia, 140 21
- Research Site
-
Praha 4 - Nusle, Czechia, 140 00
- Research Site
-
Praha 6, Czechia, 169 00
- Research Site
-
Slavkov u Brna, Czechia, 684 01
- Research Site
-
Usti nad Orlici, Czechia, 562 18
- Research Site
-
-
-
-
-
Bordeaux Cedex, France, 33076
- Research Site
-
Caen, France, 14000
- Research Site
-
La Tronche cedex, France, 38701
- Research Site
-
Marseille, France, 13253
- Research Site
-
Marseille cedex 5, France, 13385
- Research Site
-
Poitiers, France, 86021
- Research Site
-
Reims Cedex, France, 51092
- Research Site
-
Saint-Ouen, France, 93400
- Research Site
-
-
-
-
-
Berlin, Germany, 12053
- Research Site
-
Dresden, Germany, 01307
- Research Site
-
Erfurt, Germany, 99089
- Research Site
-
Villingen-Schwenningen, Germany, 78052
- Research Site
-
-
-
-
-
Baja, Hungary, 6500
- Research Site
-
Budapest, Hungary, 1076
- Research Site
-
Budapest, Hungary, 1106
- Research Site
-
Budapest, Hungary, 1037
- Research Site
-
Esztergom, Hungary, 2500
- Research Site
-
Gyor, Hungary, 9023
- Research Site
-
Kaposvar, Hungary, 7400
- Research Site
-
Kecskemet, Hungary, 6000
- Research Site
-
Miskolc, Hungary, 3526
- Research Site
-
Pecs, Hungary, 7624
- Research Site
-
Zalaegerszeg, Hungary, 8900
- Research Site
-
-
-
-
-
Ashkelon, Israel, 78278
- Research Site
-
Jerusalem, Israel, 91120
- Research Site
-
Kfar-Saba, Israel, 44281
- Research Site
-
Nahariya, Israel, 22100
- Research Site
-
Tel Aviv, Israel, 64239
- Research Site
-
Tel Hashomer, Israel, 52621
- Research Site
-
Zerifin, Israel, 70300
- Research Site
-
-
-
-
-
Ancona, Italy, 60131
- Research Site
-
Lecco, Italy, 23900
- Research Site
-
Milano, Italy, 20122
- Research Site
-
Milano, Italy, 20142
- Research Site
-
Pavia, Italy, 27100
- Research Site
-
Verona, Italy, 37126
- Research Site
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- Research Site
-
Enschede, Netherlands, 7511 JX
- Research Site
-
Rotterdam, Netherlands, 3079 DZ
- Research Site
-
Venlo, Netherlands, 5912 BL
- Research Site
-
-
-
-
-
Bialystok, Poland, 15-540
- Research Site
-
Gdansk, Poland, 80-952
- Research Site
-
Golub-Dobrzyn, Poland, 87-400
- Research Site
-
Krakow, Poland, 31-501
- Research Site
-
Lodz, Poland, 90-153
- Research Site
-
Rybnik, Poland, 44-200
- Research Site
-
Warszawa, Poland, 02-097
- Research Site
-
Warszawa, Poland, 04-749
- Research Site
-
Warszawa, Poland, 02-006
- Research Site
-
Zamosc, Poland, 87-100
- Research Site
-
-
-
-
-
Moscow, Russian Federation, 123183
- Research Site
-
Saint Petersburg, Russian Federation, 191104
- Research Site
-
Saint Petersburg, Russian Federation, 196247
- Research Site
-
Saint Petersburg, Russian Federation, 197110
- Research Site
-
Saint Petersburg, Russian Federation, 198510
- Research Site
-
Saint-Petersburg, Russian Federation, 195067
- Research Site
-
Saint-Petersburg, Russian Federation, 195257
- Research Site
-
Yaroslavl, Russian Federation, 150062
- Research Site
-
-
-
-
-
Madrid, Spain, 28041
- Research Site
-
-
Andalucía
-
Cordoba, Andalucía, Spain, 14004
- Research Site
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Research Site
-
-
Cataluña
-
Barcelona, Cataluña, Spain, 08025
- Research Site
-
Barcelona, Cataluña, Spain, 08036
- Research Site
-
Barcelona, Cataluña, Spain, 08003
- Research Site
-
Barcelona, Cataluña, Spain, 08035
- Research Site
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Research Site
-
-
-
-
-
Karlstad, Sweden, 651 85
- Research Site
-
Stockholm, Sweden, 141 86
- Research Site
-
Uppsala, Sweden, 751 85
- Research Site
-
-
-
-
-
Cambridge, United Kingdom, CB2 2QQ
- Research Site
-
Coventry, United Kingdom, CV2 2DX
- Research Site
-
London, United Kingdom, NW3 2QG
- Research Site
-
Nottingham, United Kingdom, NG5 1PB
- Research Site
-
Sheffield, United Kingdom, S5 7AU
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Research Site
-
-
Arkansas
-
Pine Bluff, Arkansas, United States, 71603
- Research Site
-
-
California
-
Azusa, California, United States, 91702
- Research Site
-
Bakersfield, California, United States, 93308
- Research Site
-
Chula Vista, California, United States, 91910
- Research Site
-
Cudahy, California, United States, 90201
- Research Site
-
Fairfield, California, United States, 94534
- Research Site
-
Glendale, California, United States, 91205
- Research Site
-
Los Angeles, California, United States, 90025
- Research Site
-
Los Angeles, California, United States, 90022
- Research Site
-
Los Angeles, California, United States, 90048
- Research Site
-
Lynwood, California, United States, 90262
- Research Site
-
Northridge, California, United States, 91324
- Research Site
-
Norwalk, California, United States, 90650
- Research Site
-
Ontario, California, United States, 91762
- Research Site
-
Riverside, California, United States, 92501
- Research Site
-
San Gabriel, California, United States, 91776
- Research Site
-
Simi Valley, California, United States, 93065
- Research Site
-
Whittier, California, United States, 90603
- Research Site
-
-
Colorado
-
Arvada, Colorado, United States, 80002
- Research Site
-
Denver, Colorado, United States, 80230
- Research Site
-
-
Connecticut
-
Stamford, Connecticut, United States, 06902
- Research Site
-
-
Florida
-
Coral Springs, Florida, United States, 33071
- Research Site
-
Lauderdale Lakes, Florida, United States, 33313
- Research Site
-
Miami, Florida, United States, 33173
- Research Site
-
Miami, Florida, United States, 33150
- Research Site
-
Ocala, Florida, United States, 34471
- Research Site
-
Pembroke Pines, Florida, United States, 33025
- Research Site
-
Pinecrest, Florida, United States, 33156
- Research Site
-
Tampa, Florida, United States, 33614
- Research Site
-
-
Georgia
-
Augusta, Georgia, United States, 30901
- Research Site
-
Macon, Georgia, United States, 31217
- Research Site
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Research Site
-
-
Illinois
-
Evanston, Illinois, United States, 60201
- Research Site
-
Gurnee, Illinois, United States, 60031
- Research Site
-
-
Indiana
-
Merrillville, Indiana, United States, 46410
- Research Site
-
Michigan City, Indiana, United States, 46360
- Research Site
-
-
Kansas
-
Wichita, Kansas, United States, 67214-2998
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Research Site
-
Lafayette, Louisiana, United States, 70503
- Research Site
-
Shreveport, Louisiana, United States, 71101
- Research Site
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01107
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Research Site
-
Detroit, Michigan, United States, 48236
- Research Site
-
Kalamazoo, Michigan, United States, 49007
- Research Site
-
Pontiac, Michigan, United States, 48341
- Research Site
-
-
Mississippi
-
Brookhaven, Mississippi, United States, 39601
- Research Site
-
Columbus, Mississippi, United States, 39705
- Research Site
-
Gulfport, Mississippi, United States, 39501
- Research Site
-
Tupelo, Mississippi, United States, 38801
- Research Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Research Site
-
Saint Louis, Missouri, United States, 63136
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Research Site
-
Reno, Nevada, United States, 89511
- Research Site
-
-
New Hampshire
-
Portsmouth, New Hampshire, United States, 03801
- Research Site
-
-
New Jersey
-
Eatontown, New Jersey, United States, 07724
- Research Site
-
-
New York
-
Bronx, New York, United States, 10461
- Research Site
-
Brooklyn, New York, United States, 11235
- Research Site
-
Brooklyn, New York, United States, 11212
- Research Site
-
Great Neck, New York, United States, 11021
- Research Site
-
Orchard Park, New York, United States, 14127
- Research Site
-
Ridgewood, New York, United States, 11385
- Research Site
-
Rosedale, New York, United States, 11422
- Research Site
-
Yonkers, New York, United States, 10704
- Research Site
-
-
North Carolina
-
Carrboro, North Carolina, United States, 27510
- Research Site
-
Charlotte, North Carolina, United States, 28207
- Research Site
-
Durham, North Carolina, United States, 27704
- Research Site
-
New Bern, North Carolina, United States, 28562
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45206
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73116
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, United States, 18017
- Research Site
-
Philadelphia, Pennsylvania, United States, 19106
- Research Site
-
Philadelphia, Pennsylvania, United States, 19118
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Research Site
-
Orangeburg, South Carolina, United States, 29118
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37408
- Research Site
-
Columbia, Tennessee, United States, 38401
- Research Site
-
Knoxville, Tennessee, United States, 37923
- Research Site
-
Nashville, Tennessee, United States, 37205
- Research Site
-
-
Texas
-
Arlington, Texas, United States, 76015
- Research Site
-
Austin, Texas, United States, 78758
- Research Site
-
Edinburg, Texas, United States, 78539
- Research Site
-
Fort Worth, Texas, United States, 76104
- Research Site
-
Fort Worth, Texas, United States, 76105
- Research Site
-
Fort Worth, Texas, United States, 76164
- Research Site
-
Grand Prairie, Texas, United States, 75050
- Research Site
-
Houston, Texas, United States, 77004
- Research Site
-
Houston, Texas, United States, 77054
- Research Site
-
Lubbock, Texas, United States, 79430
- Research Site
-
Mansfield, Texas, United States, 76063
- Research Site
-
San Antonio, Texas, United States, 78229
- Research Site
-
San Antonio, Texas, United States, 78215
- Research Site
-
San Antonio, Texas, United States, 78205
- Research Site
-
-
Virginia
-
Alexandria, Virginia, United States, 22304
- Research Site
-
Alexandria, Virginia, United States, 22306
- Research Site
-
Fairfax, Virginia, United States, 22033
- Research Site
-
Hampton, Virginia, United States, 23666
- Research Site
-
Mechanicsville, Virginia, United States, 23116
- Research Site
-
Norfolk, Virginia, United States, 23502
- Research Site
-
-
West Virginia
-
Bluefield, West Virginia, United States, 24701
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject understands the study procedures and agrees to participate in the study by giving written informed consent.
- Subject must complete the treatment and follow-up period, or have been discontinued for rising intact parathyroid hormone (iPTH), from an AMG 416 phase 3 parent study prior to the start of dosing in this study: 20120229 (NCT01785849), 20120230 (NCT01788046), or 20120359 (NCT01932970).
- Subject agrees to not participate in another study of an investigational agent during the study.
- Other Inclusion Criteria may apply
Exclusion Criteria:
- Currently receiving treatment in another investigational device or drug study.
- Currently receiving other investigational procedures while participating in this study.
- Subject has known sensitivity to any of the products or components to be administered during dosing.
- Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
Other Exclusion Criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Etelcalcetide
Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks.
Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
|
Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs)
Time Frame: From first dose until 30 days after last dose; the treatment period was 52 weeks.
|
Treatment-related adverse events are those the investigator indicated as having a reasonable possibility of having been caused by etelcalcetide.
A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: • fatal • life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • congenital anomaly/birth defect • other medically important serious event.
|
From first dose until 30 days after last dose; the treatment period was 52 weeks.
|
Number of Participants With Shift in Laboratory Values From Baseline Grade 0 or 1 to Post-baseline Grade 3 or 4
Time Frame: 52 weeks
|
Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 0 represents values in the normal range and grade 4 represents values with life-threatening consequences and urgent intervention indicated.
|
52 weeks
|
Number of Participants Who Developed Anti-etelcalcetide Antibodies
Time Frame: Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit
|
A validated dual flow-cell biosensor immunoassay was used to detect antibodies capable of binding etelcalcetide.
The number of participants with a negative or no result at baseline and positive binding antibodies at any time post-baseline is reported.
|
Baseline, Week 12, Week 24, Week 36, Week 53, the 30-day follow-up visit
|
Change From Baseline in Blood Pressure
Time Frame: Baseline and Weeks 24 and 48
|
Blood pressure (BP) values were taken post-hemodialysis assessments.
|
Baseline and Weeks 24 and 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With > 30% Reduction From Baseline in PTH During the Efficacy Assessment Phase
Time Frame: Baseline and the efficacy assessment phase, defined as the last 6 weeks prior to ending treatment for participants who completed a minimum of 8 weeks of treatment (weeks 46-52 for participants who completed 52 weeks of treatment)
|
The efficacy assessment phase (EAP) is defined as the last 6 weeks before ending treatment, which was only for participants who completed a minimum of 8 weeks of treatment with etelcalcetide.
If multiple assessments were available during the EAP, values were averaged.
|
Baseline and the efficacy assessment phase, defined as the last 6 weeks prior to ending treatment for participants who completed a minimum of 8 weeks of treatment (weeks 46-52 for participants who completed 52 weeks of treatment)
|
Percentage of Participants With > 30% Reduction From Baseline in PTH During the EAP12
Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
The efficacy assessment phase at 12 months (EAP12) was defined as the period from week 46 to 53 (inclusive).
If multiple assessments were available during the EAP12, values were averaged.
|
Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
Percentage of Participants With PTH ≤ 300 pg/mL During the EAP
Time Frame: Baseline and the efficacy assessment phase
|
Baseline and the efficacy assessment phase
|
|
Percentage of Participants With PTH ≤ 300 pg/mL During the EAP12
Time Frame: Week 46 to 53
|
Week 46 to 53
|
|
Percent Change From Baseline in Mean PTH During the EAP
Time Frame: Baseline and the efficacy assessment phase
|
Baseline and the efficacy assessment phase
|
|
Percent Change From Baseline in Mean PTH During the EAP12
Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
|
Percent Change From Baseline in Mean Corrected Calcium During the EAP
Time Frame: Baseline and the efficacy assessment phase
|
Baseline and the efficacy assessment phase
|
|
Percent Change From Baseline in Mean Corrected Calcium During the EAP12
Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
|
Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP
Time Frame: Baseline and the efficacy assessment phase
|
Baseline and the efficacy assessment phase
|
|
Percent Change From Baseline in Mean Corrected Calcium Phosphorus Product During the EAP12
Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
|
Percent Change From Baseline in Mean Phosphorus During the EAP
Time Frame: Baseline and the efficacy assessment phase
|
Baseline and the efficacy assessment phase
|
|
Percent Change From Baseline in Mean Phosphorus During the EAP12
Time Frame: Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
Baseline and the efficacy assessment phase at month 12 (weeks 46-53)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One. 2019 Mar 15;14(3):e0213774. doi: 10.1371/journal.pone.0213774. eCollection 2019.
- Bushinsky DA, Chertow GM, Cheng S, Deng H, Kopyt N, Martin KJ, Rastogi A, Urena-Torres P, Vervloet M, Block GA. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant. 2020 Oct 1;35(10):1769-1778. doi: 10.1093/ndt/gfz039. Erratum In: Nephrol Dial Transplant. 2019 May 15;:1642.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 31, 2013
Primary Completion (ACTUAL)
July 1, 2015
Study Completion (ACTUAL)
July 1, 2015
Study Registration Dates
First Submitted
February 5, 2013
First Submitted That Met QC Criteria
February 6, 2013
First Posted (ESTIMATE)
February 7, 2013
Study Record Updates
Last Update Posted (ACTUAL)
April 10, 2019
Last Update Submitted That Met QC Criteria
April 1, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20120231
- KAI-4169-008 (OTHER: KAI Pharmaceuticals, Inc (wholly owned subsidiary of Amgen Inc.))
- 2012-002808-41 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperparathyroidism, Secondary
-
The Second Hospital of Nanjing Medical UniversityRecruitingSecondary Hyperparathyroidism;ParathyroidectomyChina
-
Phramongkutklao College of Medicine and HospitalCompletedAlfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
-
Min-Sheng General HospitalTaipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaboratorsCompletedHyperparathyroidism; Secondary, RenalTaiwan
-
Chang Gung Memorial HospitalCompletedSecondary Hyperparathyroidism Due to Renal CausesTaiwan
-
Fundación SenefroAbbVie; Effice Servicios Para la Investigacion S.L.CompletedSecondary Hyperparathyroidism Due to Renal CausesSpain
-
Shanghai Zhongshan HospitalUnknownHyperparathyroidism; Secondary, Renal
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Active, not recruiting
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Deltanoid PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States
Clinical Trials on Etelcalcetide
-
Thomas Nickolas, MD MSCompletedVascular Calcification | Chronic Kidney Disease Mineral and Bone Disorder | Hyperparathyroidism; Secondary, Renal | Renal OsteodystrophyUnited States
-
Prim. Priv. Doz. Dr. Daniel CejkaAmgenCompleted
-
AmgenCompletedChronic Kidney Disease, Secondary HyperparathyroidismBelgium, United States, Germany, Poland, United Kingdom, Lithuania
-
AmgenRecruitingChronic Kidney Disease | Secondary HyperparathyroidismKorea, Republic of, United States, Turkey, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Ukraine
-
KAI PharmaceuticalsNucleus Network LtdCompletedHyperparathyroidism, SecondaryAustralia
-
AmgenCompletedSecondary HyperparathyroidismChina
-
KAI PharmaceuticalsCompletedHyperparathyroidism, SecondaryUnited States, Australia
-
AmgenCompletedSecondary Hyperparathyroidism in Patients With ESRD on HemodialysisUnited States
-
KAI PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States
-
AmgenRecruitingSecondary HyperparathyroidismUnited Kingdom, Spain, Belgium, Germany, Czechia, Poland, France, Greece, Hungary, Italy, Lithuania, Portugal